Literature DB >> 3260765

Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.

W T Hughes1.   

Abstract

The efficacies of trimethoprim (TMP)-sulfamethoxazole (SMZ), TMP-dapsone, dapsone, and pentamidine were compared for the prevention of Pneumocystis carinii pneumonia in the corticosteroid-treated-rat model. While 11 (73%) of 15 untreated control animals had P. carinii pneumonia after 10 weeks of immunosuppression, none of the animals given 125 mg of dapsone per kg daily, weekly, biweekly, or monthly had evidence of infection. Of the 10 rats given a single dose of dapsone 23 and 50 days after immunosuppression was started, 5 (50%) had P. carinii pneumonia. When three drugs were given separately to groups of 10 rats in single doses biweekly, P. carinii pneumonia occurred in 40% of those treated with TMP-SMZ and in none of those treated with TMP-dapsone; although only 2 of those treated with pentamidine survived for evaluation, both had P. carinii pneumonia. The experiments showed that dapsone is highly effective in chemoprophylaxis for P. carinii pneumonia when given at monthly intervals or more frequently and that dapsone and TMP-dapsone are more effective than is TMP-SMZ when given at biweekly intervals. It seems reasonable to expect that biweekly doses of dapsone or TMP-dapsone would provide an effective and reasonably safe chemoprophylaxis regimen for patients at high risk for P. carinii pneumonia, and studies to test such a scheme are justifiable. Biweekly doses are preferred over monthly doses to allow for occasional inadvertent omission of doses expected from patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260765      PMCID: PMC172241          DOI: 10.1128/AAC.32.5.623

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  The diposition of the antileprotic drug dapsone (DDS) in Philippine subjects.

Authors:  J H Peters; G R Gordon; D C Ghoul; J G Tolentino; G P Walsh; L Levy
Journal:  Am J Trop Med Hyg       Date:  1972-07       Impact factor: 2.345

2.  Five-year absence of Pneumocystis carinii pneumonitis in a pediatric oncology center.

Authors:  W T Hughes
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

3.  Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients.

Authors:  H Jick
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

4.  Attempts at prophylaxis for murine Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; H K Kim; R A Price; C Miller
Journal:  Curr Ther Res Clin Exp       Date:  1973-08

5.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

6.  Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men.

Authors:  H S Jaffe; D I Abrams; A J Ammann; B J Lewis; J A Golden
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

7.  Failure of pentamidine isethionate to provide chemoprophylaxis against Pneumocytis carinii infection in rats.

Authors:  K A Western; L Norman; A G Kaufmann
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

8.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; S Kuhn; S Chaudhary; S Feldman; M Verzosa; R J Aur; C Pratt; S L George
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

9.  Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Dapsone in saliva and plasma of man.

Authors:  J H Peters; J F Murray; G R Gordon; R H Gelber
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

View more
  6 in total

1.  Pneumocystis carinii: A review of an important opportunistic pathogen in AIDS.

Authors:  M J Gill; R Read
Journal:  Can J Infect Dis       Date:  1991

2.  Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.

Authors:  M Mirochnick; E Cooper; K McIntosh; J Xu; J Lindsey; D Jacobus; L Mofenson; J L Sullivan; W Dankner; L M Frenkel; S Nachman; D W Wara; D Johnson; V R Bonagura; M H Rathore; C K Cunningham; J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

Authors:  J Falloon; J Lavelle; D Ogata-Arakaki; A Byrne; A Graziani; A Morgan; M A Amantea; K Ownby; M Polis; R T Davey
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

4.  Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.

Authors:  S Merali; Y Zhang; D Sloan; S Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice.

Authors:  D C McFadden; M A Powles; J G Smith; A M Flattery; K Bartizal; D M Schmatz
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

6.  Low-dose trimethoprim-sulfamethoxazole alone and in association with zidovudine for prevention and treatment of murine Pneumocystis carinii pneumonia.

Authors:  M Brun-Pascaud; P M Girard; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.